Clinical Trials Logo

Cirrhosis clinical trials

View clinical trials related to Cirrhosis.

Filter by:

NCT ID: NCT01072721 Completed - Cystic Fibrosis Clinical Trials

Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis

PEDISCAN
Start date: January 19, 2010
Phase: N/A
Study type: Interventional

Early diagnosis of liver fibrosis is useful for the follow-up and treatment of chronic liver disease. At present, the unique validated method to evaluate the liver fibrosis in children, is the liver biopsy which is an invasive method. If the elastometry method is proved to be a good method to evaluate the fibrosis in children, a numerous liver biopsy could be avoided.

NCT ID: NCT01060813 Completed - Cirrhosis Clinical Trials

Study of the Benefit of Exercise and Aminoacid Supplements in Cirrhotic Patients

Start date: January 2010
Phase: N/A
Study type: Interventional

This is a pilot study including 20 cirrhotic patients that will be randomized to receive during 3 months leucine vs leucine plus a programme of physical exercise specially designed for cirrhotic patients. The hypothesis is that physical exercise in cirrhotic patients could increase muscle mass (and therefore glutamine synthetase activity leading to a higher blood ammonium clearance) and quality of life. Safety of physical exercise in cirrhotic patients will be strictly assessed.

NCT ID: NCT01050530 Completed - Cirrhosis Clinical Trials

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

Start date: December 2009
Phase: Phase 3
Study type: Interventional

OPC-41061 at 7.5 mg/day or placebo will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and the change in body weight from baseline at the time of the final administration will be compared between the two groups.

NCT ID: NCT01048788 Completed - Cirrhosis Clinical Trials

A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg

Start date: December 2009
Phase: Phase 3
Study type: Interventional

OPC-41061 will be orally administered at 7.5 mg/day for 7 days to cirrhosis patients with ascites despite having received conventional diuretic therapy. Based on the change in body weight, on Day 7 it will be decided whether to continue administration at the same dose or to increase the dose, and then OPC-41061 will be orally administered for an additional 7 days at either 7.5 mg/day or, if diuretic effect for the initial 7-day administration is insufficient, at an increased dose of 15 mg/day. Plasma drug level, efficacy, and safety of OPC-41061 by 14-day repeated administration will be investigated.

NCT ID: NCT00999167 Completed - Cirrhosis Clinical Trials

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

HALT-HE
Start date: December 2009
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).

NCT ID: NCT00986817 Completed - Cirrhosis Clinical Trials

Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin

TERAS
Start date: November 2009
Phase: Phase 3
Study type: Interventional

Ascites is a common complication of cirrhosis. Sodium restriction and diuretics are the first step treatment. Refractory ascites (not responding to first step treatment) is treated with repeated large volume paracentesis followed by intra venous albumin expansion. In pilot studies vasoconstrictor agents such as terlipressin have shown beneficial effect on ascites production. Therefore the investigators will study the effect of combined therapy with albumin and terlipressin on recidivation ascites.

NCT ID: NCT00968695 Completed - Cirrhosis Clinical Trials

Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.

Start date: July 2009
Phase: Phase 4
Study type: Interventional

Effects of long term albumin administration on the cardiocirculatory and renal function and hepatic hemodynamics in patients with advanced cirrhosis and ascites.

NCT ID: NCT00926224 Completed - Cirrhosis Clinical Trials

Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients

Start date: July 2009
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate the diagnostic performance of the XL probe for estimating degree of liver fibrosis/cirrhosis in obese patients > 28 kg/m² with various liver diseases in patients with chronic liver disease scheduled for a liver biopsy.

NCT ID: NCT00921349 Completed - Cirrhosis Clinical Trials

A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis

Start date: December 2004
Phase: Phase 4
Study type: Interventional

The value of banding ligation plus beta blocker in the prophylaxis of first episodes of variceal bleeding has not yet been evaluated. This study was conducted to compare the efficacy and safety of banding ligation plus nadolol versus nadolol in the prophylaxis of first bleeding in cirrhotic patients with high-risk esophageal varices.

NCT ID: NCT00905996 Completed - Cirrhosis Clinical Trials

Primary Prophylaxis of Gastric Varix Bleed

Start date: August 2006
Phase: N/A
Study type: Interventional

In patients who have never bled from gastric varix (GOV2 and IGV1), cyanoacrylate injection will be better than both beta-blocker therapy and no treatment in prevention of gastric variceal bleed. The investigators conducted a randomized controlled trial in patients with gastric varix (GOV2 and IGV1) who never bled before, to study the efficacy of treatment with cyanoacrylate injection versus beta-blocker versus no treatment in prevention of first bleed from gastric varices.